Learn more about the safety and efficacy results of KEDRAB® (Rabies Immune Globulin [Human]), which was shown to be appropriate and effective for use as an important component of post-exposure prophylaxis (PEP) in a Phase 4 clinical study of pediatric patients.1
KEDRAB is designed, dosed, and packaged in accordance with American Society of Hospital Pharmacists (ASHP) guidelines on preventing medication errors.2
References: 1. Hobart-Porter N, Stein M, Toh N, Amega N, Nguyen HB, Linakis J. Safety and efficacy of rabies immunoglobulin in pediatric patients with suspected exposure. Hum Vaccin Immunother. 2021;17(7):2090-2096. doi:10.1080/21645515.2020.1854000. 2. Billstein-Leber M, Carrillo CJD, Cassano AT, Moline K, Robertson JJ. ASHP Guidelines on Preventing Medication Errors in Hospitals. Am J Health Syst Pharm. 2018;75:1493-1517. doi:10.2146/ajhp170811.